



Wednesday 3rd of September						
0900-1300	0900-1300 ANCR Boardmeeting, Room:					
Pre-symposium - regsitration and workshops						
1300-1400	1300-1400 Registration, Baguettes, and refreshments					
1400-1700	1400-1700 Workshop 1:ICD-O-4 – Coding and registration					
1400-1700	1400-1700 Workshop 2: Artificial Intelligence (AI) and Cancer					
1400-1700	1400-1700 Workshop 3: Clinical Quality Registries and Quality Improvement in Cancer					
Social Schedule						
1740 Meetup	1740 Meetup outside the hotel for those who would like to walk as a group to Edda					
1800-1900	1800-1900 Edda reception					
1900-2000	1900-2000 Exploring Reykjavik on our way from EDDA to SKOR					
2000 -	2000 - SKOR: dart and burger					
						
Thursday 4th of September						
Welcome, posters overview, keynote						
0900-0915	Sigríður Gunnarsdóttir - Director og the Icelandic Cancer Registry - Welcome					
0915-0930	Álfréður Haraldsdóttir ICR - Raffle rules and poster overview					
0930-1000	Keynote - Dr. Þórunn Rafnar: "A 28 Year Partnership: The Impact of the Icelandic Cancer Registry and deCODE Genetics"					
1000-1015	Short break					
Session 1: Epidemiology and socioeconomic factors						
	Oral presentations	Presenter	ID	Poster presentation: Be present by poster 11.05-11.25	Presenter	ID
1015-1025	Trends in early-onset cancer incidence rates in the Nordic countries 2003-2022	A. L.V. Johansson	67	Second primary cancers in patients with a pharyngeal index tumour: a register-based cohort study	Elli Hirvonen	7
1025-1035	Incidence rates of prostate-specific antigen testing, prostatic biopsy, and prostate cancer in Denmark.	Frederik Knude Palshof	168	Equity assessment of cancer detection	Ulf Strömberg	35
1035-1045	Across the lifespan: Age-specific incidence trends of breast cancer subtypes in Sweden	Leo Gkekos	88	HPV is no longer just a women's concern. Long-Term HPV-related Cancer Trends in Norway	Thea E. Hetland Falkenthal	38
1045-1055	Long-term risk of cervical precancer and cancer by human papillomavirus genotype and entry cytology	Maija Elina Aurora Vahteristo	125	Estimated numbers and trends of children affected by paternal cancer in Finland between 1970 and 2022	Annina Kyrölähti	50
1055-1105	Key findings from the South African childhood cancers report 2021, by the National Cancer Registry	Natasha Abraham	131	Forecasting cancer prevalence in Finland	Eetu Emelil Mäkinen	77
1105-1125	Coffee break and poster walk			Prostate Cancer Incidence and Mortality among Immigrants in Finland Between 2000 and 2017 – a Register-Based Cohort Study	Maarit Lamminmäki	107
1125-1135	Use of beta blockers and risk of ovarian cancer: results from two nationwide nested case-control studies	Meyya Bouazzi	152	Cumulative cancer incidence & mortality by smoking, BMI, and alcohol use: preliminary results from a population-based study (JA PreventNCD project)	Toni Myllyaho	109
1135-1145	Rising breast cancer incidence in Iceland – What role does BMI play?	Álfréður Haraldsdóttir	166	Cancer incidence and mortality among persons in the Finnish Register of Employees Exposed to Carcinogens	Sanna Heikkinen	123
1145-1155	Primary prevention policies to reduce tobacco and alcohol consumption and future cancer burden in the Nordic countries	Amy Rose Tickle	148	Childhood vaccinations and risk of leukaemia in children: a population-based cohort study in Scandinavia	Marie Hargreave	135
1155-1205	Associations between socioeconomic status and stage-specific incidences of intrahepatic cholangiocarcinoma in Sweden, 2011-2021	Juan Vaz	36	Maternal hormonal contraception use and the risk of childhood cancer: A systematic review and meta-analysis	Sif E. Carlsen	157
1205-1225	Short break and poster walk			Occupational exposures and risk of disease, injuries and death among offshore petroleum workers and their children: a study protocol	Mieke C Louwe	179
1225-1235	NOCCA-NEW: Even newer news	Jan Ivar Martinsen	170	Sex Differences in Cancer Incidence and Survival: A Danish Nationwide Population-Based Study Assessing 35 Cancer Sites	Fie Stegenborg	162
				Sex- and anatomical site-specific incidence trends of cutaneous squamous cell carcinoma, keratoacanthoma and precursor lesions in Denmark, 2005-2023	Kirstine Duffau	167
Session 2: Outcomes and treatment						
	Oral presentations	Presenter	ID	Poster presentation: Be present by poster 12.05-12.25	Presenter	ID
1235-1245	Quality indicators for lung cancer – a Nordic overview	Marit Enny Gismarvik	164	Real-World Outcomes in Multiple Myeloma Following Implementations of New Swedish National Guidelines: Data from Swedish Myeloma Registry (2008-2024)	Anna Elisabeth Genell	83
1245-1255	Economic Burden of Chronic Myeloid Leukemia in Sweden: 2015 to 2030	Enoch Yi-Tung Chen	103	Anti-HER2 treatment in Norway: how we treat older women differently	Sarah Hjorth	85
1255-1305	Patient reported outcomes one year after diagnosis. A Norwegian nationwide study for eleven different cancers	Yiva Maria Gjølsvik	156	Risk of thrombosis and bleeding in patients diagnosed with myeloproliferative neoplasms (MPN)	Stefanie Antonilli	91
1305-1400	Lunch and poster walk			Evaluating the quality of care using clinical registries within the Slovenian cancer registry: a case of skin melanoma clinical registry	Vesna Zadnik	121
1400-1410	Breast cancer in Iceland 2004-2023: adjuvant endocrine therapy adherence in early-stage hormone receptor positive breast cancer	Stefanía Katrín Finnisdóttir	178	Locoregional recurrence of breast cancer in Finland over 20 years of follow-up	Laura Niinikoski	129
1410-1420	Autolink: A statistical model for automatic linking of medical treatment to cancer case	Sigríð Leithe	92	Surgical treatment of melanoma in Norway – results from the norwegian melanoma registry	Hilde Hedemann Brenn	132
1420-1430	Targeted Therapy in the Treatment of Lung Cancer in Iceland, 2010–2023	Stefanía Ásta Tryggvadóttir	122	Comorbidity prevalence trends among cancer patients aged 75 and older in Finland	Anne Declunder	153
1430-1440	Treatment pathways of Finnish lung cancers in 2018-2022	Salla Elissa Toikkanen	161	Beyond the Registry: Mapping Quality of Life and Survivorship in Icelandic Cancer Patients	Sigríður Gunnarsdóttir	160
1440-1500	Coffee break and poster walk			Sex differences in the occurrence of adverse effects associated with fluoropyrimidine-based chemotherapy	Elsa Jónsdóttir	172
Session 3: Survival						
	Oral presentations	Presenter	ID	Poster presentation: Be present by poster 14.40-15.00	Presenter	ID
1500-1510	Prognostic value of the neutrophil-to-lymphocyte ratio in individuals undergoing fluoropyrimidine-based chemotherapy	Elsa Jónsdóttir	173	Ovarian cancer survival by histotype and residual disease status after surgery: results from the Norwegian Clinical Registry for Gynecological Cancer	Cassia Bree Trewin-Nybråten	52
1510-1520	Is categorising cancer stages as I-IV too crude? A microsimulation study on breast cancer survival, socioeconomic position and stage at	Elisavet Syriopoulou	112	Lasso regularization and flexible parametric survival cure models to improve complete cancer prevalence predictions	Fabrizio Di Mari	65
1520-1530	An alternative approach to analyzing and reporting survival for all cancer sites combined	Paul Lambert	128	Are age-trends in breast cancer survival different across subtypes?	Katrin Ásta Gunnarsdóttir	73
1530-1540	Effects of aspirin at diagnosis on the survival of colorectal cancer patients: a 20-year population-based study.	Arnar Agustsson	142	Sex differences in stage at diagnosis, treatment, and survival for lung, colorectal, and head and neck cancers: a Danish registry-based study	Fie Stegenborg	134
1540-1550	Modelling the time-varying effect of hormonal treatment on metastasis-free survival among ER+ breast cancer patients	Keith Humphreys	151	Exploring complementary methods for analysis of regional differences in cancer survival - an example from the Norwegian childhood cancer registry	Mads K. Rohde	140
1550-1600	Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumour quality registry	Cassia Bree Trewin-Nybråten	55	Sex differences in melanoma survival across age of diagnosis	Anna Oksanen	141
				Comparison and analysis of cancer survival in patients with large intramuscular, or extramuscular soft tissue sarcomas in Sweden	Pia Löthgren	158
Social schedule						
1745	Meet-up for bus					
1800-1830	Bus to Skótaskólinn Hveradólm					
1900-2200	Symposium Dinner at Skótaskólinn Hveradólm					
2200-2300	Bus to Reykjavik					
						
Friday 5th of September						
0900-0930	Keynote - Dr. Sigurður Yngvi Kristinsson: "Screening for multiple myeloma and its precursors - the iStopMM study"					
Session 4: Screening and registration						
	Oral presentations	Presenter	ID	Poster presentation: Be present by poster 10.10-10.30	Presenter	ID
0930-0940	Nordic colorectal cancer screening programmes: a comparison of organization, operation and quality indicators	Susanne Føgh Jørgensen	66	Does distance affect screening participation? A cohort study on the discontinuation of mobile breast cancer screening in Denmark	Camilla Rahr Tatarli	44
0940-0950	Customized Cancer Statistics	Anna Skog	87	Using longitudinal causal inference methods to estimate the effect of mammography screening on breast cancer death in the Danish population	Jonas Schmidt	80
0950-1000	Was it excess incidence or true overdiagnosis? Systematic review of the reported data from randomised controlled trials of mammography	Sisse Njor	48	Estimating breast cancer screening's impact on mortality using target trial emulation	Casper Urth Pedersen	82
1000-1010	Effect of reminder calls in language of origin on screening participation: a randomized controlled trial in ColorectalScreen Norway	Nadia Iqbal	63	Ensuring the coherence of the cancer database of the Finnish Cancer Registry	Minna Merkivi	86
1010-1040	Break and poster walk			Cost-effectiveness of PRS-stratified screening for breast cancer in the Finnish setting	Filip Siegfrieds	105
1040-1050	Regression discontinuity design reveals the local effect of FIT-based colorectal cancer screening on cancer incidence	Anne Mette Kristensen	79	Unwarranted of the Swedish Myeloma Register: Assessing Data Consistency with Original Clinical Records	Anna Elin Margareta Källsgård	106
1050-1100	EUCanScreen approach for use of individual level data for cancer screening programme monitoring	Aapeli Nevala	93	Unvaliated hysterectomies - using swedish regional cancer registries to detect overdiagnosis of Endometrioid Intraepithelial Neoplasia (EIN)	Chenyang Zhang	114
1100-1110	Increased cervical cancer incidence among screening target aged women – variation by mode of cancer detection	Maiju Pankakoski	97	Re-attendance in BreastScreen Norway after a false positive screening result	Solveig Hofvind	117
1110-1120	Use of FIT-values to decide differentiated screening-intervals in colorectal cancer screening – a nationwide register-based cohort study.	Signe Bülow Therkildsen	99	Artificial Intelligence in Mammography Screening in Norway (AIMS Norway)	Solveig Hofvind	118
1120-1130	How the choice of a sensitivity measure affects the laboratory rankings in the Danish cervical cancer screening program	Cecilie Mai Bæk	102	Towards the European Health Data Space	Bjarte Aagnes	174
	1130-1200 Coffee break and poster walk			The immortal life of poorly managed data: technical debt in registry-based research	Ronnie Babigumira	181
1200-1210	Longitudinal changes in mammographic density by breast in a screening cohort	Solveig Hofvind	116			

1210-1220	Colorectal cancer incidence after FIT-invitation in the 70's – Is screening in the 70's beneficial?	Pernille Thordal Larsen	133	
1220-1230	Comparison of cytological and HPV-based screening within population-based screening program in Finland	Veli-Matti Partanen	150	
1230-1300	1230-1300 Closure, AWARD and raffle draw			